🇺🇸 pemetrexed (Alimta) in United States

16 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 16

Most-reported reactions

1. Dyspnoea — 4 reports (25%)
2. Malignant Neoplasm Progression — 2 reports (12.5%)
3. Pleural Effusion — 2 reports (12.5%)
4. Pneumonia — 2 reports (12.5%)
5. Atrial Fibrillation — 1 report (6.25%)
6. Bacterial Infection — 1 report (6.25%)
7. Blood Pressure Fluctuation — 1 report (6.25%)
8. Chest Discomfort — 1 report (6.25%)
9. Chest Pain — 1 report (6.25%)
10. Drug Intolerance — 1 report (6.25%)

Source database →

Frequently asked questions

Is pemetrexed (Alimta) approved in United States?

pemetrexed (Alimta) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for pemetrexed (Alimta) in United States?

National Cheng-Kung University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.